TenderlineUK
Procurement Intelligence
Official OCDS
Find a Tender
complete
Official procurement procedure

11C]PBR28 PET and MRI scanning, radioligand production, LPS (lipopolysaccharid) supply and biomarker analysis

Medical imaging services
Research laboratory services
South West (UKK)
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: University of Exeter: "11C]PBR28 PET and MRI scanning, radioligand production, LPS (lipopolysaccharid) supply and biomarker analysis". Published status: complete. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
Contracting AuthorityUniversity of ExeterScope & CategoriesNot publishedSubmission Window
complete
No deadline published
Submission GatewayDirect notice routeLegal Basis & RegimeStandard procurementEstimated Value (exc. VAT)Not published
Bidder Intelligence · Authority Profile: University of Exeter
Market Analytics
View Authority Profile →
Derived from OCDS awards & bid statistics
Published history for University of Exeter. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Published-to-award variance
Not availableInsufficient comparable data
Requires at least 5 comparable procedures
Competition Density
31.4Bids / Report
14.3% of reports have one bid
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate available
Payment Terms
Check noticePublished terms
Payment obligations depend on the applicable regime and contract. Consult the official documents.
Coverage: 117 active published awards; 91 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Published-to-award variance compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityUniversity of Exeter
Procedure methodNot published
Procurement categoryNot published
Statuscomplete
Framework / DPSNot published
CompetitionNot published
Above thresholdNot published
Legal basisNot published
Tender period startsNot published
Clarification deadlineNot published
Electronic submissionNot published
Submission languagesNot published
Published8 Jul 2021, 14:08 BST
Last source update8 Jul 2021, 14:08 BST
Recurring procurementNot published
ClassificationMedical imaging services, Research laboratory services
Delivery area
South West (UKK)
OCIDocds-h6vhtk-02c587
What is being bought
PET and MRI scanning, radioligand production, LPS (lipopolysaccharid) supply and biomarker analysis
What changed
From the official release history
  1. Status changed to complete
    8 Jul 2021, 14:08 BST
  2. Official notice release published
    8 Jul 2021, 14:08 BST
  3. Buyer information updated
    8 Jul 2021, 14:08 BST
Lots and requirements (1)
Published by the contracting authority
  • Lot 1 · #1
    Individual lot title not published
    Status not published
    Published valueNot published
    PET and MRI scanning, radioligand production, LPS (lipopolysaccharid) supply and biomarker analysis • Only UK provider of PET tracers [11C]BU90008, [11C]SA4503, and [18F]BCPP-EF, that are currently used for our studies. • Invicro is located within the Hammersmith Hospital Campus, its location accommodates research participants for image and clinical assessments without increased burden and travel for the participants. While also reducing cost and time to conduct the studies. • [11C] tracers (with short half-life of about 20 minutes) and of [18F] radiotracers (with half-life of about 120 minutes) are produced in house and the short half-life of the [11C] tracers means Invicro’s two in-house cyclotron’s must be used. Their radioligand development platform means implementation of new tracers is not available at other facilities. • Invicro has the equipment and facilities to collect arterial blood samples during the scans and analyze the quantity of the radioactive metabolites on site.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
Timeline
  1. Procedure published
    8 Jul 2021, 14:08 BST
  2. Award active
    Not published · Not published
  3. Contract active
    Signed 6 Jul 2021, 00:00 BST · £726,480
Commercial outcome and competition
Awards
Invicro
Not published · Not published · active
Contracts
[11C]PBR28 PET and MRI scanning, radioligand production, LPS (lipopolysaccharid) supply and biomarker analysis
£726,480 · signed 6 Jul 2021, 00:00 BST · active
Bid statisticsNo aggregate bid statistics published
Buyer and organisations in this procedure

University of Exeter

Contracting authority GB-FTS-1655
View buyer profile

  • University of Exeter
    buyer

    RC000653
    Northcote House, Exeter, UKK, EX4 4QH
    samantha.barker@exeter.ac.uk
    +44 11111

  • Invicro
    supplier

    London, UKI

  • Royal Court of Justice
    reviewBody

    London
Documents (0)
Official links; attachments are not copied
No data
No linked documents are published
Related procedures (0)
No data
No related procedures published
Planning and rationale
Planning budgetNot published
No-engagement rationaleNot published
Procedure rationalePET and MRI scanning, radioligand production, LPS (lipopolysaccharid) supply and biomarker analysis • Only UK provider of PET tracers [11C]BU90008, [11C]SA4503, and [18F]BCPP-EF, that are currently used for our studies. • Invicro is located within the Hammersmith Hospital Campus, its location accommodates research participants for image and clinical assessments without increased burden and travel for the participants. While also reducing cost and time to conduct the studies. • [11C] tracers (with short half-life of about 20 minutes) and of [18F] radiotracers (with half-life of about 120 minutes) are produced in house and the short half-life of the [11C] tracers means Invicro’s two in-house cyclotron’s must be used. Their radioligand development platform means implementation of new tracers is not available at other facilities. • Invicro has the equipment and facilities to collect arterial blood samples during the scans and analyze the quantity of the radioactive metabolites on site.